We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients previously treated with three classes of antiretrovirals can achieve
maximal viral suppression when starting a regimen of Fuzeon in combination
with an active boosted protease inhibitor and other anti-HIV drugs, according
to new study data.
Myriad Genetics will begin a second Phase I clinical trial with its investigative
cancer drug, MPC-6827, under an FDA-approved investigational new drug application.
Medicure, a cardiovascular drug discovery and development company, has reached
full enrollment in its 120-patient advanced Phase II MATCHED trial evaluating
MC-4232, in patients with co-existing diabetes and hypertension.
The Immune Response, a biopharmaceutical company dedicated to becoming a leading
immune-based therapy company in HIV and multiple sclerosis (MS), has announced
a new Phase II study to investigate the long-term safety, mechanism-of-action,
and utility of a quarterly dosing regimen of NeuroVax, an investigational T-cell
receptor peptide vaccine for multiple sclerosis.
Samaritan Pharmaceuticals, a developer of innovative drugs, has announced it
is rapidly progressing with its Phase II/III study of SP-01A, a new kind of
pill that, Samaritan believes, blocks the AIDS virus before it ever enters the
human cell.
The FDA has granted final approval for Teva Pharmaceutical's abbreviated new
drug application for methylprednisolone acetate injectable suspension, 40
mg/mL and 80 mg/mL in single-dose vials.
Vicuron Pharmaceuticals has been granted priority review status for its
investigational agent dalbavancin, a novel once-weekly antibiotic for the
treatment of complicated skin and soft tissue infections.